These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9440351)

  • 21. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: whole blood flow cytometric analysis of lymphocyte function.
    Barten MJ; Rahmel A; Boldt A; Dhein S; Bittner HB; Tarnok A; Mohr FW; Gummert JF
    Comput Biol Med; 2007 Oct; 37(10):1367-73. PubMed ID: 17182025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herbal teas interfere with cyclosporin levels in renal transplant patients.
    Nowack R; Nowak B
    Nephrol Dial Transplant; 2005 Nov; 20(11):2554-6. PubMed ID: 16046518
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacologic monitoring and outcomes of cyclosporine.
    Pollard SG
    Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored?
    Filler G
    Nephrol Dial Transplant; 2005 Jun; 20(6):1032-4. PubMed ID: 15814537
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Twenty-five years of cyclosporin use in transplantation medicine].
    Hesselink DA; van Hagen PM; Balk AH; van Hal PT; Weimar W; van Gelder T
    Ned Tijdschr Geneeskd; 2003 May; 147(20):959-64. PubMed ID: 12784529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives.
    Wei L; Steiner JP; Hamilton GS; Wu YQ
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4549-51. PubMed ID: 15357990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cyclosporine A].
    Loeb I; Hermans P
    Rev Stomatol Chir Maxillofac; 2005 Apr; 106(2):119-20. PubMed ID: 15924103
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
    Kahan BD
    Transplant Proc; 2004 Mar; 36(2 Suppl):378S-391S. PubMed ID: 15041372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo pharmacological effects of ciclosporin and some analogues.
    Borel JF; Baumann G; Chapman I; Donatsch P; Fahr A; Mueller EA; Vigouret JM
    Adv Pharmacol; 1996; 35():115-246. PubMed ID: 8920206
    [No Abstract]   [Full Text] [Related]  

  • 33. [The mechanism of action of cyclosporine: something more than immunosuppression?].
    Losa García JE; Jiménez López A; Pérez Arellano JL
    Rev Clin Esp; 1996 May; 196(5):313-21. PubMed ID: 8768033
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic drug monitoring of cyclosporin G.
    Yatscoff RW; Langman L; LeGatt DF
    Ther Drug Monit; 1995 Dec; 17(6):655-9. PubMed ID: 8588236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclosporine.
    O'Marcaigh AS; Betcher DL
    J Pediatr Oncol Nurs; 1996 Apr; 13(2):98-100. PubMed ID: 8854993
    [No Abstract]   [Full Text] [Related]  

  • 36. [New natural immunosuppressants. A comparison by their mechanism of action with cyclosporin A].
    Sazykin IuO; Bykov VA
    Antibiot Khimioter; 2000; 45(1):25-31. PubMed ID: 10690425
    [No Abstract]   [Full Text] [Related]  

  • 37. Lack of pharmacodynamic interaction between trimetazidine and cyclosporin A in human lymphoproliferative and mouse delayed hypersensitivity response models.
    Albengres E; Tillement JP; d'Athis P; Salducci D; Chauvet-Monges AM; Crevat A
    Fundam Clin Pharmacol; 1996; 10(3):264-8. PubMed ID: 8836700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does cyclosporin promote the secretion of transforming growth factor-beta 1 following pulmonary transplantation?
    el-Gamel A; Awad M; Yonan N; Keevil B; Egan J; Campbell C; Rahman AN; Haselton P; Deiraniya AK; Hutchinson IV
    Transplant Proc; 1998 Jun; 30(4):1525-7. PubMed ID: 9636621
    [No Abstract]   [Full Text] [Related]  

  • 39. The isolation, structural characterization, and immunosuppressive activity of cyclosporin G (NVa2-cyclosporine) metabolites.
    Copeland KR; Yatscoff RW
    Ther Drug Monit; 1991 Jul; 13(4):281-8. PubMed ID: 1780958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of the properties and mechanisms of action of cyclosporine with an emphasis on dermatological therapy in dogs, cats and people.
    Robson D
    Vet Rec; 2003 Jun; 152(25):768-72. PubMed ID: 12846287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.